Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION CDISC CEO Advises Drug Makers to Collect Data Based on CDASH
August 27, 2014
-
REGULATORY PAFSC Second Committee to Review Nobelpharma’s Anticancer Drug Streptozocin on Sept. 5
August 26, 2014
-
BUSINESS Latuda Goes on Sale in UK: Sumitomo Dainippon
August 25, 2014
-
BUSINESS Pfizer Japan to Create New Unit for its Innovative Drug Business in December
August 22, 2014
-
ACADEMIA Kyoto University, Astellas Aim to Develop Immunological Disease Cures, 11 Target Molecules Now under Screening
August 21, 2014
-
BUSINESS MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
-
BUSINESS Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
-
BUSINESS Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
-
BUSINESS Genzyme Japan Appoints Former Bausch & Lomb Japan President Ashikaga as Its New President
August 18, 2014
-
REGULATORY 148 Blopress Generics OKed, Competition with AGs Likely upon December Listing
August 15, 2014
-
REGULATORY PMDA Will Prosper by Promoting Review Work, Research, and Training Together: Chief Executive
August 13, 2014
-
ORGANIZATION Fair Discussions Necessary for Full Introduction of New Drug Development Premium: Chuikyo Member
August 12, 2014
-
BUSINESS Asahi Kasei Pharma Aims to Achieve Sales Target of 100 Billion Yen in FY2015 Despite Debut of Flivas Generics: President
August 11, 2014
-
BUSINESS Linical Aims to Become “One-Stop” CRO for Global Clinical Trials
August 8, 2014
-
BUSINESS Daiwa Corporate Investment Establishes Venture Capital Firm Specializing in Biopharmaceuticals; Sights Set on Seeds of University Origin
August 7, 2014
-
REGULATORY MHLW to Survey Rate of Generic Drug Use Under High-Cost Healthcare System; Regulatory Reform Council Concerned that System Provides Little Incentive to Use Generics
August 6, 2014
-
ACADEMIA JSH to Adopt Tougher COI Rule after Panel Said Novartis’s Involvement in SIGN Trial Should Have Been Disclosed at Conference
August 5, 2014
-
BUSINESS Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
-
REGULATORY MHLW to Fund Research Aimed at Obtaining Additional Indications for Intractable and Orphan Diseases for Existing Drugs
August 4, 2014
-
REGULATORY PAFSC First Committee Backs Approval of MSD’s Insomnia Treatment
August 4, 2014
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…